1. Fletcher CD. The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification. Histopathology. 2014;64(1):2–11.
2. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75.
3. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493–501.
4. Li X, Liu R, Shi T, Dong S, Ren F, Yang F, et al. Primary pulmonary malignant fibrous histiocytoma: case report and literature review. J Thorac Dis. 2017;9(8):E702–8.
5. Serrano C, Romagosa C, Hernández-Losa J, Simonetti S, Valverde C, Moliné T, et al. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. Cancer. 2016;122(1):99–107.